BNO - 2008 Annual General Meeting - Dr Deborah Rathjen, CEO and MD
Tue, 11 Nov 2008 12:30pm
BIONOMICS LIMITED (BNO)
Loading presentation... If nothing happens, you may need to install Flash and/or enable javascript in your browser.
Dr Deborah Rathjen
Bionomics Limited presents at the ASX Small to Mid Caps conference in New York
Mon, 2 Apr 2012 1:00pm
Deborah Rathjen, CEO and Managing Director
Dr Deborah Rathjen
Bionomics targets Alzheimer`s Disease
Mon, 20 Feb 2012 11:05am
Dr Deborah Rathjen, Managing Director
Dr Deborah Rathjen
Bionomics 2011 Annual General Meeting
Fri, 11 Nov 2011 9:45am
Dr Deborah Rathjen, Managing Director, CEO
Dr Deborah Rathjen
Bionomics Limited - ASX Small to Mid Caps Conference in Singapore and Hong Kong
Fri, 4 Nov 2011 11:25am
Deborah Rathjen, Managing Director & CEO
Dr Deborah Rathjen
Bionomics to present at the ASX Small to Mid Caps conference in Hong Kong and Singapore
Thu, 6 Oct 2011 10:15am
Dr Deborah Rathjen, CEO
Dr Deborah Rathjen
Clinical trials reach key milestones for Bionomics
Fri, 12 Aug 2011 11:30am
Dr Deborah Rathjen, Managing Director
Dr Deborah Rathjen
Bionomics Anti-Anxiety Drug Clinical Trials Successful Results - Dr Deborah Rathjen, Managing Director & CEO
Tue, 5 Apr 2011 2:00pm
Dr Deborah Rathjen
BNC210 - European Approval Granted for Two Phase Ib Trials - Dr Deborah Rathjen, Managing Director
Mon, 11 Oct 2010 11:00am
Dr Deborah Rathjen
Second BNC210 Phase 1 Clinical Trial Commences - Dr Deborah Rathjen, Managing Director & CEO
Thu, 13 May 2010 10:30am
BNC210 is being developed for the treatment of anxiety and depression
Dr Deborah Rathjen
Bionomics Provides Update on BNC105 and BNC210
Thu, 4 Feb 2010 12:30pm
Icon_lastIcon_nextIcon_previousIcon_first